Oxaliplatin Injection, Solution
Product Images NDC 25021-233

6 FDA label images from Sagent Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 25021-233). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Oxa0c 0008 01)

Structural Formula (Oxa0c 0008 01)
Chemical structure of oxaliplatin. The diagram shows the platinum (Pt) atom coordinated with a cyclohexane ring structure containing amine groups (NH2) and two carboxylate groups (O-C=O), representing the molecular configuration of the active ingredient oxaliplatin.*
FDA Label Image

Figure 1 (Oxa0c 0008 02)

Figure 1 (Oxa0c 0008 02)
A Kaplan-Meier survival curve showing Disease-Free Survival Probability (DFS) over time in months, comparing two treatment arms labeled FOLFOX4 and LV5FU2. The graph includes hazard ratio, number of events, and number of patients at risk for each time interval.*
FDA Label Image

Figure 2 (Oxa0c 0008 03)

Figure 2 (Oxa0c 0008 03)
A Kaplan-Meier survival curve chart depicting disease-free survival (DFS) probability over time in months, comparing two treatment arms: FOLFOX4 and LV5FU2, for Stage III patients. The graph includes a hazard ratio with 95% confidence interval and a logrank test p-value, illustrating statistical comparison between treatments.*
FDA Label Image

Figure 3 (Oxa0c 0008 04)

Figure 3 (Oxa0c 0008 04)
A survival curve chart comparing the percentage of patients surviving over 24 months for three treatment groups: Oxaliplatin Injection plus FU/LV, Oxaliplatin Injection plus Irinotecan, and Irinotecan plus FU/LV. The chart shows median survival times for each group and a statistical significance indicator (p<0.0001).*
FDA Label Image

Package Label – Principal Display Panel – Vial Label (Oxa0c 0008 05)

Package Label – Principal Display Panel – Vial Label (Oxa0c 0008 05)
Label for Oxaliplatin Injection, USP 50 mg per 10 mL (5 mg per mL) intravenous solution. The label states it is for intravenous use only, supplied in a 10 mL single-dose vial, and is manufactured for Sagent Pharmaceuticals. It highlights that the product is sterile, nonpyrogenic, preservative-free, and contains oxaliplatin 5 mg/mL in water. Additional warnings and handling instructions related to dilution and storage are included, alongside a caution that it is a cytotoxic agent. The label includes a barcode and lot/expiration date section.*
FDA Label Image

Package Label – Principal Display Panel – Vial Label (Oxa0c 0008 06)

Package Label – Principal Display Panel – Vial Label (Oxa0c 0008 06)
Oxaliplatin 100 mg per 20 mL (5 mg per mL) injection, USP, intravenous solution in a 20 mL single-dose vial. The label includes cautions for cytotoxicity and instructions not to mix with sodium chloride solutions. Manufactured for Sagent Pharmaceuticals, Schaumburg, IL, marked with NDC 25021-233-20.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.